Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Demyelinating Disease following Anti-TNFa Treatment: A Causal or Coincidental Association? Report of Four Cases and Review of the Literature.

Andreadou E, Kemanetzoglou E, Brokalaki Ch, Evangelopoulos ME, Kilidireas C, Rombos A, Stamboulis E.

Case Rep Neurol Med. 2013;2013:671935. doi: 10.1155/2013/671935.

2.

[Neurological adverse events under anti-TNF alpha therapy].

Cohen M, Baldin B, Thomas P, Lebrun C.

Rev Neurol (Paris). 2012 Jan;168(1):33-9. doi: 10.1016/j.neurol.2011.06.005. French.

PMID:
22098827
3.

Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.

McLeod C, Bagust A, Boland A, Dagenais P, Dickson R, Dundar Y, Hill RA, Jones A, Mujica Mota R, Walley T.

Health Technol Assess. 2007 Aug;11(28):1-158, iii-iv. Review.

4.

Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy.

Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H.

Arthritis Res Ther. 2010;12(3):R117. doi: 10.1186/ar3054.

5.

Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

Wollina U, Hansel G, Koch A, Schönlebe J, Köstler E, Haroske G.

Am J Clin Dermatol. 2008;9(1):1-14. Review. Erratum in: Am J Clin Dermatol. 2008;9(5):347.

PMID:
18092839
6.

Onset or exacerbation of cutaneous psoriasis during TNFalpha antagonist therapy.

Wendling D, Balblanc JC, Briançon D, Brousse A, Lohse A, Deprez P, Humbert P, Aubin F.

Joint Bone Spine. 2008 May;75(3):315-8. doi: 10.1016/j.jbspin.2007.06.011.

PMID:
18329935
7.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

8.

Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.

Gao X, Wendling D, Botteman MF, Carter JA, Rao S, Cifaldi M.

J Med Econ. 2012;15(6):1054-63. doi: 10.3111/13696998.2012.692341.

PMID:
22563743
9.

Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy.

Lozeron P, Denier C, Lacroix C, Adams D.

Arch Neurol. 2009 Apr;66(4):490-7. doi: 10.1001/archneurol.2009.11.

PMID:
19364934
10.
11.

A case of leukoencephalopathy associated with adalimumab-treated rheumatoid arthritis and a review of literature.

Ryu YS, Park SH, Kim JM, Kim EJ, Lee J, Kwok SK, Ju JH, Kim HY.

Rheumatol Int. 2012 Nov;32(11):3481-5. doi: 10.1007/s00296-011-2216-0. Review.

PMID:
22065075
12.

Demyelination during anti-TNFα therapy for ankylosing spondylitis.

Mercieca C, Vella N, Borg AA.

Mod Rheumatol. 2012 Apr;22(2):303-7. doi: 10.1007/s10165-011-0498-4.

PMID:
21748364
14.

Anti-tumour necrosis factor alpha therapy and increased risk of de novo psoriasis: is it really a paradoxical side effect?

Joyau C, Veyrac G, Dixneuf V, Jolliet P.

Clin Exp Rheumatol. 2012 Sep-Oct;30(5):700-6. Review.

PMID:
22935567
15.

Membranous glomerulonephritis with the use of etanercept in ankylosing spondylitis.

Kaushik P, Rahmani M, Ellison W.

Ann Pharmacother. 2011 Dec;45(12):e62. doi: 10.1345/aph.1Q492.

PMID:
22116994
16.

Emergence of Crohn's disease during treatment with the anti-tumor necrosis factor agent etanercept for ankylosing spondylitis: possible mechanisms of action.

Haraoui B, Krelenbaum M.

Semin Arthritis Rheum. 2009 Dec;39(3):176-81. doi: 10.1016/j.semarthrit.2008.06.004.

PMID:
18706681
17.

Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings.

Bonafede M, Fox KM, Watson C, Princic N, Gandra SR.

Adv Ther. 2012 Aug;29(8):664-74. doi: 10.1007/s12325-012-0037-5.

PMID:
22886712
18.

Autoimmune diseases induced by TNF-targeted therapies: analysis of 233 cases.

Ramos-Casals M, Brito-Zerón P, Muñoz S, Soria N, Galiana D, Bertolaccini L, Cuadrado MJ, Khamashta MA.

Medicine (Baltimore). 2007 Jul;86(4):242-51.

19.

Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register.

Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP; British Society for Rheumatology Biologics Register..

Arthritis Res Ther. 2009;11(2):R52. doi: 10.1186/ar2670.

20.
Items per page

Supplemental Content

Support Center